​

​

Advokat, C. D., Comaty, J. E., & Julien, R. M. (2019). Juliens primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth.

 

Amoroso, T., & Workman, M. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30(7), 595-600. doi:10.1177/0269881116642542

 

Amsterdam, J. V., Opperhuizen, A., & Brink, W. V. (2011). Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology, 59(3), 423-429. doi:10.1016/j.yrtph.2011.01.006

​

Brambilla, R., Vigna-Taglianti, F., Avanzi, G., Faggiano, F., & Leone, M. (2012). Gamma-hydroxybutyrate (GHB) for mid/long term treatment of alcohol dependence: A systematic review. Rivista Di Psichiatria, 47(4), 269-280. Retrieved September 23, 2021.

 

Bogenschutz, M. P., & Pommy, J. M. (2012). Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Testing and Analysis, 4(7-8), 543-555. doi:10.1002/dta.1376

 

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299. doi:10.1177/0269881114565144

​

Bratsos, S., & Saleh, S. N. (2019). Clinical Efficacy of Ketamine for Treatment-resistant Depression. Cureus. doi:10.7759/cureus.5189

 

Caputo, F., Vignoli, T., Maremmani, I., Bernardi, M., & Zoli, G. (2009). Gamma Hydroxybutyric Acid (GHB) for the Treatment of Alcohol Dependence: A Review. International Journal of Environmental Research and Public Health, 6(6), 1917-1929. doi:10.3390/ijerph6061917

​

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., . . . Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. doi:10.1073/pnas.1119598109

 

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., . . . Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853-4858. doi:10.1073/pnas.1518377113

 

Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse, 45(2), 161-169. doi:10.1080/00952990.2018.1545024

 

De Gregorio, D., Popic, J. P., Enns, J. K., Inserra, A. P., Skalecka, A. U., Markopoulos, A. U., . . . Gobbi, G. U. (2021). Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proceedings of the National Academy of Sciences, 118(5). doi:10.1073/pnas.2020705118

 

Frecska, E., Bokor, P., & Winkelman, M. (2016). The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. Frontiers in Pharmacology, 7. doi:10.3389/fphar.2016.00035

 

Frood, A. (2015). Ayahuasca psychedelic tested for depression. Nature. doi:10.1038/nature.2015.17252

 

Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020). Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Frontiers in Psychiatry, 10. doi:10.3389/fpsyt.2019.00943

​

Gallimberti, L., Cibin, M., Pagnin, P., Sabbion, R., Pani, P. P., Pirastu, R., . . . Gessa, G. L. (1993). Gamma-Hydroxybutyric Acid for Treatment of Opiate Withdrawal Syndrome. Neuropsychopharmacology, 9(1), 77-81. doi:10.1038/npp.1993.45

 

Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology, 29(1), 57-68. doi:10.1177/0269881114555249

 

González, D., Torrens, M., & Farré, M. (2015). Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. BioMed Research International, 2015, 1-9. doi:10.1155/2015/643878

​

Grady, S. E., Marsh, T. A., Tenhouse, A., & Klein, K. (2017). Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature. Mental Health Clinician, 7(1), 16-23. doi:10.9740/mhc.2017.01.016

 

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . . . Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. doi:10.1177/0269881116675513

 

Grob, C. S., Danforth, A. L., & Chopra, G. S. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Arch Gen Psychiatry.

 

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. doi:10.1177/0269881114548296

 

Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., . . . Carhart-Harris, R. L. (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Scientific Reports, 11(1). doi:10.1038/s41598-021-81446-7

 

Krebs, T. S., & Johansen, P. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994-1002. doi:10.1177/0269881112439253

 

Krebs, T. S., & Johansen, P. (2013). Psychedelics and Mental Health: A Population Study. PLoS ONE, 8(8). doi:10.1371/journal.pone.0063972

​

Leone, M. A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., & Faggiano, F. (2010). Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd006266.pub2

​

Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology, 9. doi:10.3389/fphar.2018.00529

 

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). MDMA-assisted psychotherapy may help individuals with treatment-resistant PTSD. PsycEXTRA Dataset. doi:10.1037/e717552011-010

​

Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., . . . Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9), 2735-2745. doi:10.1007/s00213-019-05249-5

 

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder. The Journal of Clinical Psychiatry, 67(11), 1735-1740. doi:10.4088/jcp.v67n1110

​

Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2017). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37-46. doi:10.1080/00952990.2017.1310218

​

Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2018). Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Molecular Psychiatry, 24(7), 1040-1052. doi:10.1038/s41380-018-0028-2

 

Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012). A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology, 27(1), 40-52. doi:10.1177/0269881112464827

 

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180. doi:10.1177/0269881116675512

 

Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology, 30(12), 1220-1229. doi:10.1177/0269881116679368

 

Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016). The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. Journal of Psychopharmacology, 30(12), 1230-1247. doi:10.1177/0269881116652578

 

Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014). The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Current Neuropharmacology, 12(5), 444-461. doi:10.2174/1570159x12666140619204251

​

Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology, 30(4), 344-353. doi:10.1177/0269881116628430

​

Taylor, G. T., & Manzella, F. (2016). Kappa Opioids, Salvinorin A and Major Depressive Disorder. Current Neuropharmacology, 14(2), 165-176. doi:10.2174/1570159x13666150727220944

​

Treston, G., Bell, A., Cardwell, R., Fincher, G., Chand, D., & Cashion, G. (2009). What is the nature of the emergence phenomenon when using intravenous or intramuscular ketamine for paediatric procedural sedation? Emergency Medicine Australasia, 21(4), 315-322. doi:10.1111/j.1742-6723.2009.01203.x